Skip to main content
A breakthrough in the treatment of multiple myeloma

Service(s) concerned

Structure(s) concerned



A breakthrough in the treatment of multiple myeloma

Current treatments for this bone marrow cancer do not allow cure but remission. The I-Dara protocol promoted by Caen Normandy University Hospital offers a better tolerated and more effective treatment.

Promising research work

Multiple myeloma is a rare bone marrow cancer (5,500 new cases/year in France) which mainly concerns elderly patients (the average age at diagnosis is 70 years) and for which current treatments do not allow a cure but a more or less prolonged remission.

The I-Dara protocol is a non-comparative study which involved frail elderly patients (80 years or over, or with significant associated pathologies) in relapse. The treatment included the combination of immunotherapy and high-dose cortisone-free oral therapy, which allowed better tolerance of the treatment which was extended up to 5 years in certain patients with good effectiveness.

With 55 patients included, the remission duration is on average 18 months and 3 out of 4 patients are still alive at more than 2 years.

This work has been the subject of several communications. The study has just been completed and will be published.

A study carried out by teams from the Hematology Institute of Basse Normandie with the support of the research and innovation department.

Communication department of Caen Normandy University Hospital
CHU Caen Normandy

Press contacts

Communication Department
Avenue de la Côte de Nacre
CS 30001
14033 CAEN cedex 9